Takeji Umemura

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Masashi Mizokami, Osamu Yokosuka, Tetsuo Takehara et al. · The Lancet Infectious Diseases · 2015 · 362 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population

Minoru Nakamura, Nao Nishida, Minae Kawashima et al. · The American Journal of Human Genetics · 2012 · 271 citations · Full text

Life Sciences, Genetics, Molecular Genetics +12

Immunoglobin G4‐hepatopathy

Takeji Umemura, Yoh Zen, Hideaki Hamano et al. · Hepatology · 2007 · 251 citations · Full text

Medicine, Internal Medicine, Pathology +16

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 <scp>HCV</scp> infection: an open‐label, phase 3 trial

Masao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno et al. · Journal of Viral Hepatitis · 2014 · 202 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17